This antibody recognizes CD99, an approximately 32 kDa sialoglycoprotein expressed on many cell types, with particularly strong expression on Ewing´s sarcoma and peripheral primitive neuroectodermal tumors. Within the hematopoietic system, CD99 is expressed on virtually all cell types except granulocytes.
CD99
Reaktivität: Human
FACS, WB, IHC (p), IP
Wirt: Maus
Monoclonal
MEM-131
unconjugated
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg/mL (> 95% pure by SDS-PAGE)
Buffer
Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody at 2 - 8 °C up to one month or (in aliquots) at -20 °C for longer.
Target
CD99
Andere Bezeichnung
CD99 / MIC2
Hintergrund
CD99 is a ubiquitous transmembrane type I sialoglycoprotein of a unique and poorly characterized protein family. CD99 is heavily O-glycosylated and was described as a T cell costimulator and strong activator of integrin-mediated actin cytoskeleton assembly, promoting cell adhesion and homotypic aggregation, immediate arrest on an inflamed vascular endothelium, and cell migration through it. Ligation of CD99 under some conditions can lead to apoptosis. Originally CD99 was described as a human thymus leukemia antigen, an Ewing´s sarcoma-specific membrane marker, and an adhesion molecule involved in spontaneous rosette formation of T cells with erythrocytes.Synonyms: 12E7, E2 antigen, MIC2X, MIC2Y, Protein MIC2, T-cell surface glycoprotein E2